Prothena Corporation plc

NASDAQ PRTA

Data sourced from

and

Download Data

Prothena Corporation plc Gross Working Capital 1 year YoY Change (%) for the quarter ending March 31, 2024: -19.54%

Prothena Corporation plc Gross Working Capital 1 year YoY Change (%) is -19.54% for the quarter ending March 31, 2024, a -175.10% change year over year. Gross working capital is a financial metric that represents the amount of a company's current assets available to cover its current liabilities and short-term debt obligations. It is calculated by subtracting the sum of current liabilities and short-term debt from the total current assets of a company. Gross working capital provides insights into a company's short-term liquidity and its ability to meet its financial obligations in the near future. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.

Prothena Corporation plc Gross Working Capital for the quarter ending March 31, 2023 was USD 646.57 M, a 26.02% change year over year.
Prothena Corporation plc Gross Working Capital for the quarter ending March 31, 2022 was USD 513.07 M, a 58.73% change year over year.
Prothena Corporation plc Gross Working Capital for the quarter ending March 31, 2021 was USD 323.23 M, a -4.20% change year over year.
Prothena Corporation plc Gross Working Capital for the quarter ending March 31, 2020 was USD 337.40 M, a -14.68% change year over year.

NASDAQ: PRTA

Prothena Corporation plc

CEO	Dr. Gene G. Kinney Ph.D.
IPO Date	Dec. 21, 2012
Location	Ireland
Headquarters	77 Sir John Rogerson?s Quay, Dublin, Ireland, 2
Employees	173
Sector	Healthcare
Industry	Biotechnology

Description

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.

Key trends